Emerging therapeutics for primary peritoneal cancer

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96
   PubMed Web of Science ®Google Scholar
• Pfisterer J, Plante M, Vergote I, Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006;24:4699-707
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Mahner S, Kaern J, A. A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG) (abstract LBA 5509). J Clin Oncol 2009;27:18s
   Google Scholar
• Huang L, Cronin KA, Johnson KA, Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer? Cancer 2008;112:2289-300
   PubMed Web of Science ®Google Scholar
• Bookman MA, Brady MF, McGuire WP, Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009;27:1419-25
   PubMed Web of Science ®Google Scholar
• Hopfl G, Ogunshola O, Gassmann M. HIFs and tumors--causes and consequences. Am J Physiol Regul Integr Comp Physiol 2004;286:R608-23
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004;9(Suppl 1):2-10
   PubMed Web of Science ®Google Scholar
• Burger RA. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 2007;25:2902-8
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
   PubMed Web of Science ®Google Scholar
• Burger RA, Sill MW, Monk BJ, Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:5165-71
   PubMed Web of Science ®Google Scholar
• Cannistra SA, Matulonis UA, Penson RT, Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180-6
   PubMed Web of Science ®Google Scholar
• Garcia AA, Hirte H, Fleming G, Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008;26:76-82
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Bookman MA, Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J Clin Oncol 2010;28:15s (Abstr LBA1)
   Google Scholar
• Tew W, Colombo N, Ray-Caquard I. VEGF-trap for patients with recurrent platinum resistant epithelial ovarian cancer (abstract 5508). J Clin Oncol 2008;25:18s
   Google Scholar
• Friedlander M, Hancock KC, Benigno B. Pazopanib (GW 786034) is active in women with advanced epithelial ovarian, fallopian tube, and peritoneal cancers: results of a phase II study (abstract 5561). J Clin Oncol 2007;25:18s
   Google Scholar
• Ledermann JA, Rustin GA, Hackshaw A. A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC) (abstract 5501). J Clin Oncol 2009;27:15s
   Google Scholar
• Hirte HW, Vidal L, Fleming GF. A phase II study of cedirinab (AZD2171) in recurrent or persistant ovarian, peritoneal, or fallopian tube cancer: Final results of a PMH, Chicago, and California consortia trial (abstract 5521). J Clin Oncol 2008;26:298s
   Google Scholar
• Matulonis UA, Berlin S, Ivy P, Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009;27:5601-6
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Adnane L, Newell P, Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-40
   PubMed Web of Science ®Google Scholar
• Matei DS, Sill MW, DeGeest K, Bristow RE. Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group study. J Clin Oncol 2008;26: abstract 5537
   PubMedGoogle Scholar
• Welch S, Hirte H, Elit L. CA125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib – a trial of the PMH phase II consortium (abstract 5519). J Clin Oncol 2007;25:18s
   Google Scholar
• Azad NS, Posadas EM, Kwitkowski VE, Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008;26:3709-14
   PubMed Web of Science ®Google Scholar
• Polcher M, Eckhardt M, Coch C, Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. Cancer Chemother Pharmacol;66:203-7
   PubMed Web of Science ®Google Scholar
• Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000;103:253-62
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Tsuda H, Takano M, Expression of platelet-derived growth factors and their receptors in ovarian clear-cell carcinoma and its putative precursors. Mod Pathol 2008;21:115-24
   PubMed Web of Science ®Google Scholar
• Henriksen R, Funa K, Wilander E, Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 1993;53:4550-4
   PubMed Web of Science ®Google Scholar
• Lassus H, Sihto H, Leminen A, Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma. Br J Cancer 2004;91:2048-55
   PubMed Web of Science ®Google Scholar
• Wilczynski SP, Chen YY, Chen W, Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. Hum Pathol 2005;36:242-9
   PubMed Web of Science ®Google Scholar
• Matei D, Emerson RE, Lai YC, Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Oncogene 2006;25:2060-9
   PubMed Web of Science ®Google Scholar
• Loizos N, Xu Y, Huber J, Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target. Mol Cancer Ther 2005;4:369-79
   PubMed Web of Science ®Google Scholar
• Thayer SP, di Magliano MP, Heiser PW, Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003;425:851-6
   PubMed Web of Science ®Google Scholar
• Watkins DN, Berman DM, Baylin SB. Hedgehog signaling: progenitor phenotype in small-cell lung cancer. Cell Cycle 2003;2:196-8
   PubMed Web of Science ®Google Scholar
• Berman DM, Karhadkar SS, Maitra A, Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003;425:846-51
   PubMed Web of Science ®Google Scholar
• Karhadkar SS, Bova GS, Abdallah N, Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 2004;431:707-12
   PubMed Web of Science ®Google Scholar
• Spannuth WA, Sood AK, Coleman RL. Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther 2010;10:431-7
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bicher A, Coleman RL, Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha, in platinum-sensitive ovarian cancer in first relapse. J Clin Oncol 2008;26: abstract 5500
   Web of Science ®Google Scholar
• Naumann RW, Symanowski JT, Ghamande SA, PRECEDENT:A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer (abtract LBA5021b). J Clin Oncol 2010;28:18s
   Google Scholar
• Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004;26:882-93
   PubMed Web of Science ®Google Scholar
• Dantzer F, de La Rubia G, Menissier-De Murcia J, Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1. Biochemistry 2000;39:7559-69
   PubMed Web of Science ®Google Scholar
• McCabe N, Turner NC, Lord CJ, Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66:8109-15
   PubMed Web of Science ®Google Scholar
• Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008;26:3785-90
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-17
   PubMed Web of Science ®Google Scholar
• Fong PC, Spicer J, Reade S. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of a small molecule inhibitor of poly ADP-ribose polymerase (PARP), KU-0059436 (Ku) in patients (p) with advanced tumours(abstract 3022). J Clin Oncol 2006;24:18s
   Google Scholar
• Yap TA, deBono J, Boss D. First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA 1/2 mutation carriers (abstract 3529). J Clin Oncol 2007;25
   PubMedGoogle Scholar
• Fong PC, Boss DS, Carden CP. AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: results from a phase I study. J Clin Oncol 2008;26: abstract 5510
   Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34
   PubMed Web of Science ®Google Scholar
• Sandhu SK, Wenham RM, Wilding G, First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers (abstract 3001). J Clin Oncol 2010;28:15s
   PubMedGoogle Scholar
• Vergote IB, Micha JP, Pippitt CH. Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer (abstract 5013). J Clin Oncol 2010;28:7s
   Google Scholar
• Carden CP, Boss DS, Fong PC, A phase I study of AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor: results in patients with BRCA deficient ovarian cancer (BDOC). National Cancer Research Institute Cancer Conference; 2008
   Google Scholar
• Makhija S, Amler LC, Glenn D, Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 2010;28:1215-23
   PubMed Web of Science ®Google Scholar